These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8054905)

  • 1. Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
    Chatterjee R; Mills W; Katz M; McGarrigle HH; Goldstone AH
    Bone Marrow Transplant; 1994 May; 13(5):519-22. PubMed ID: 8054905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germ cell damage and Leydig cell insufficiency in recipients of nonmyeloablative transplantation for haematological malignancies.
    Kyriacou C; Kottaridis PD; Eliahoo J; McKeag N; Bomford J; McGarrigle HH; Linch DC; Mackinnon S; Chatterjee R
    Bone Marrow Transplant; 2003 Jan; 31(1):45-50. PubMed ID: 12621506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
    Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
    Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of gonadal function in post-pubertal patients after bone marrow transplantation during childhood objective].
    Pérez Rodríguez MJ; Alonso Blanco M; Otheo De Tejada Barasoain E; Maldonado Regalado MA; Muñoz Villa A; Barrio Castellanos R
    An Esp Pediatr; 2000 Oct; 53(4):324-9. PubMed ID: 11083981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases.
    Somali M; Mpatakoias V; Avramides A; Sakellari I; Kaloyannidis P; Smias C; Anagnostopoulos A; Kourtis A; Rousso D; Panidis D; Vagenakis A
    Gynecol Endocrinol; 2005 Jul; 21(1):18-26. PubMed ID: 16048797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence.
    Ishiguro H; Yasuda Y; Tomita Y; Shinagawa T; Shimizu T; Morimoto T; Hattori K; Matsumoto M; Inoue H; Yabe H; Yabe M; Shinohara O; Kato S
    Bone Marrow Transplant; 2007 Apr; 39(8):483-90. PubMed ID: 17334386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Martín A; Pérez-Simón JA; Caballero MD; López-Holgado N; Vázquez L; del Cañizo MC; San Miguel JF
    Haematologica; 2005 Jan; 90(1):78-85. PubMed ID: 15642673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
    Carlson K; Smedmyr B; Hagberg H; Oberg G; Simonsson B
    Bone Marrow Transplant; 1993 Mar; 11(3):205-8. PubMed ID: 8467284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.
    Houck W; Abonour R; Vance G; Einhorn LH
    J Clin Oncol; 2004 Jun; 22(11):2155-8. PubMed ID: 15169802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
    Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
    Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Leydig cell insufficiency in adult males following bone marrow transplantation for haematological malignancies.
    Chatterjee R; Kottaridis PD; McGarrigle HH; Eliahoo J; McKeag N; Mackinnon S; Goldstone AH
    Bone Marrow Transplant; 2001 Sep; 28(5):497-502. PubMed ID: 11593324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
    Jost LM; Honegger HP; Stahel RA
    Schweiz Med Wochenschr; 2000 Jan; 130(3):60-9. PubMed ID: 10683881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
    Re D; Bamborschke S; Feiden W; Schröder R; Lehrke R; Diehl V; Tesch H
    Bone Marrow Transplant; 1999 Feb; 23(3):295-8. PubMed ID: 10084263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.